About GCCL

With an exclusive lab service available for clinical trials and a logistics system that meets global quality standards,
GCCL is building trust with over 200 partners in Asia by providing a sample analysis service spanning
the entire cycle of clinical trials to meet customer demands.

Company News

홈   >   About GCCL   >   Newsroom   >   Company News

Meet us at ESMO 2025

2025. 09. 25


Hello from GCCL.

GCCL, a leading central lab based in APAC, is exhibiting at ESMO 2025 from October 17–20 in Berlin, Germany!

As the largest oncology-focused scientific congress in Europe, 
ESMO brings together pharmaceutical companies, biotech firms, research institutions, and clinical experts 
from around the world each year to share the latest cancer research findings and clinical trial innovations.



GCCL will be joining as part of the Korea delegation led by KoNECT (Korea National Enterprise for Clinical Trials) and 
will showcase its customized analytical services and APAC Central Lab capabilities at KoNECT’s booth #2019.







Oncology is the most actively studied field in clinical trials and a core area in the development of innovative therapeutics.


In particular, GCCL offers differentiated expertise in oncology clinical trials,

and we look forward to discussing potential global clinical trial partnerships with you at our ESMO booth.



[Integrated Sample Analysis Services]
Comprehensive analysis of various clinical samples, including blood, tissue, and fluids,

ensuring standardized data quality across multinational clinical trials.


[Advanced Bioanalytical Platforms]
Cutting-edge technologies such as LC-MS/MS, ddPCR, and Flow Cytometry enable precise PK, PD, and

biomarker analysis for oncology and immuno-oncology drugs.


[GCLP Certification & Global Quality Standards]
Accredited with GCLP, ISO 15189, and NGSP, GCCL meets the stringent quality standards

required by global sponsors and regulatory authorities.


[Biomarker Research & Immune Monitoring]
Enhanced capabilities in biomarker analysis, including ADCs and TPDs,

to support the development of next-generation targeted cancer therapies.



As a trusted partner delivering end-to-end clinical trial sample analysis services for drug development, 
GCCL looks forward to meeting you at ESMO 2025.






Please feel free to contact us!
📩 Email: GCCL@gccorp.com



GCCL is committed to being your most reliable clinical trial partner, delivering value and trust across every project.
Click the banner below to learn more about us!